Study of combination treatment for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIB, IIIC, or IV non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has not been treated for this stage.
- Your tumor tests positive for high levels of PD-L1 (at least 50% of tumor cells).
- You are able to have pembrolizumab (an immunotherapy) as a single treatment.
- If you have brain metastases, they must be treated and stable, or you have up to 5 small, untreated asymptomatic brain lesions.
- You have not had certain prior treatments for your advanced lung cancer (like chemotherapy or immunotherapy) or if you had adjuvant therapy, it was more than 6 months before this study starts.
- You do not have certain medical conditions like other active cancers, serious lung problems, uncontrolled diabetes, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This study tests a new medicine called PF-08634404 (an antibody-drug conjugate that targets cancer cells) combined with other anti-cancer drugs in people with advanced non-small cell lung cancer. It aims to see if these combinations are safe and effective. You may be eligible if your cancer has not responded to prior treatments or if you have not received any systemic treatment for advanced disease.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.